



IFW

PTO/SB/21 (09-04)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	10/807,635	
	Filing Date	March 23, 2004	
	First Named Inventor	Daniel E. AFAR	
	Art Unit	1642	
	Examiner Name	C. Joyce	
Total Number of Pages in This Submission	5	Attorney Docket Number	511582001111

ENCLOSURES (Check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Reply to Missing Parts/Incomplete Application <input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____ <input type="checkbox"/> Landscape Table on CD	<input type="checkbox"/> After Allowance Communication to TC <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): Substance of Examiner Interview (2 pages); Corrections to Examiner's Amendment (2 pages) Return Receipt Postcard
<input type="checkbox"/> Remarks		CUSTOMER NO.: 36327

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT			
Firm Name	MORRISON & FOERSTER LLP		
Signature	<i>Kate H. Murashige</i>		
Printed name	Kate H. Murashige		
Date	January 26, 2007	Reg. No.	29,959

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the U.S. Postal Service on the date shown below with sufficient postage as First Class Mail, in an envelope addressed to: MS AF, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Dated: January 26, 2007

Signature: *Judy Calem* (Judy Calem)


I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: MS AF, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: January 26, 2007

Signature: 

(Judy Calvert)

Docket No.: 511582001111
(PATENT)



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Daniel E. AFAR et al

Application No.: 10/807,635

Filed: March 23, 2004

For: NOVEL 13-TRANSMEMBRANE PROTEIN
EXPRESSED IN PROSTATE CANCER

Confirmation No.: 4032

Art Unit: 1642

Examiner: Catherine Joyce

SUBSTANCE OF EXAMINER INTERVIEW UNDER 37 C.F.R. §1.33(B)

MS AF
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

This reply is in response to the Examiner's Interview Summary of December 15, 2006 which was mailed to us with the Notice of Allowance on January 10, 2007 for which a response is due on February 10, 2007. Accordingly, this response is timely filed.

Please enter the following into record:

Applicants acknowledge the summary of the interview conducted with the Examiner.
Applicants agree with the Substance of the Interview as described by the Examiner.

Applicants have noted a couple of typographical errors in the presentation of the amendments, and on the next page have reproduced the claims indicating the change from the claims as typed in the amendment, which differ by virtue of these errors from those on file.

In summary, in claim 42(c), "GTE5" should be "GTE9" and in claim 45, the designation number should be 207129, not 207084. Applicants further noted that in the Examiner's amendment, in claims 45 and 46, the addition of the words "the full" was not indicated by an underline. Applicants hope that any confusion created by this can be resolved based on this submission.

In the event the U.S. Patent and Trademark office determines that an extension and/or other relief is required, applicant petitions for any required relief including extensions of time and authorizes the Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to Deposit Account No. 03-1952 referencing Docket No. 511582001111. However, the Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Dated: January 26, 2007

Respectfully submitted,

By Kate H. Murashige

Kate H. Murashige

Registration No.: 29,959

MORRISON & FOERSTER LLP

12531 High Bluff Drive

Suite 100

San Diego, California 92130-2332

Tel.: (858) 720-5112

Fax.: (858) 720-5125

Corrections to Examiner's Amendment

42. An isolated nucleic acid molecule which comprises a nucleotide sequence that

(a) encodes a protein comprising the amino acid sequence of SEQ ID NO: 2 or a variant thereof at least 90% identical thereto, wherein amino acid substitutions are conservative amino acid substitutions, which variant raises antibodies that specifically bind the extracellular region of the protein consisting of the amino acid sequence of SEQ ID NO: 2; or

(b) encodes the protein encoded by a cDNA contained in the plasmid designated p24P4C12-GTE5 deposited with American Type Culture Collection as Designation No. 207129; or

(c) encodes the protein encoded by a cDNA contained in the plasmid designated ~~p24P4C12-GTE5~~ p24P4C12-GTE9 deposited with American Type Culture Collection as Designation No. 207084; or

(d) comprises a nucleotide sequence fully complementary to the entire length of the nucleotide sequences designated in paragraphs (a)-(c).

43. The nucleic acid molecule of claim 42 which comprises a nucleotide sequence that encodes a protein comprising the amino acid sequence of SEQ ID NO: 2 or a variant thereof at least 90% identical thereto, wherein amino acid substitutions are conservative amino acid substitutions, which variant raises antibodies that specifically bind the extracellular region of the protein consisting of the amino acid sequence of SEQ ID NO: 2, or the full complement of said nucleotide sequence over its entire length.

44. The nucleic acid molecule of claim 43 wherein said nucleotide sequence encodes the amino acid sequence of SEQ ID NO: 2 or the full complement of said nucleotide sequence over its entire length.

45. The nucleic acid of claim 42 which comprises a nucleotide sequence that encodes the protein encoded by a cDNA contained in the plasmid designated p24P4C12-GTE5 deposited with American Type Culture Collection as Designation No. 207084 207129 or the full complement of said nucleotide sequence over its entire length.

46. The nucleic acid molecule of claim 42 which comprises a nucleotide sequence that encodes the protein encoded by a cDNA contained in the plasmid designated p24P4C12-GTE9 deposited with American Type Culture Collection as Designation No. 207084 or the full complement of said nucleotide sequence over its entire length.

48. The nucleic acid molecule of claim 42 which comprises SEQ ID NO: 1 from nucleotide residue number 6 through nucleotide residue number 2138 or the full complement of said nucleotide sequence over its entire length.

49. A recombinant expression system which comprises the nucleotide sequence contained in the nucleic acid molecule of claim 42 operably linked to control sequences for expression.

50. Isolated recombinant host cells comprising the expression system of claim 49.

51. A method to produce a protein having the characteristics of 24P4C12 which method comprises culturing the cells of claim 50 under conditions for expression, and optionally recovering said protein.